<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610504</url>
  </required_header>
  <id_info>
    <org_study_id>13DUR503</org_study_id>
    <nct_id>NCT02610504</nct_id>
  </id_info>
  <brief_title>Prospective Single Center Open Label Study of Shoulder OA Pain</brief_title>
  <official_title>A 26 Week Prospective Open Label Clinical Study Evaluating A Single Intra-Articular Injection of Durolane 3ml for Treatment of Osteoarthritis Pain of the Shoulder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, prospective, single cohort study of Durolane 3ml intra-articular injection into&#xD;
      the shoulder for pain in mild to moderate patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects 19-85 years old will receive a single intra-articular (IA) injection of DUROLANEÂ®&#xD;
      3mL given for the relief of pain in the treatment of symptomatic osteoarthritis (OA) of the&#xD;
      shoulder followed over a 26-week time period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2015</start_date>
  <completion_date type="Actual">May 23, 2017</completion_date>
  <primary_completion_date type="Actual">May 23, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shoulder pain on movement (SPOM) 0-100mm VAS</measure>
    <time_frame>over 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shoulder pain at night (SPAN) 0-100mm VAS</measure>
    <time_frame>over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Assessment form</measure>
    <time_frame>over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PGA)</measure>
    <time_frame>over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder pain rescue medication diary</measure>
    <time_frame>over 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, concomitant medications, physical exam</measure>
    <time_frame>over 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Durolane 3ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection into shoulder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durolane</intervention_name>
    <description>single injection of 3ml</description>
    <arm_group_label>Durolane 3ml</arm_group_label>
    <other_name>Hyaluronic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of glenohumeral osteoarthritis&#xD;
&#xD;
          -  SPOM score greater than or equal to 50 in study shoulder&#xD;
&#xD;
          -  Willing to discontinue oral and topical analgesia other than rescue acetaminophen&#xD;
&#xD;
          -  abstinence from any other IA or per-articular injections for the shoulder during the&#xD;
             course of the trial&#xD;
&#xD;
          -  patients with chronic shoulder pain lasting more than 6 months without clinically&#xD;
             significant improvement in pain over the past one month&#xD;
&#xD;
          -  pain at least 50% of the days during previous month&#xD;
&#xD;
          -  patients who have failed conventional therapy of NSAIDs or steroid injections&#xD;
&#xD;
          -  patients with a retained active range of motion of at least 30% in all directions to&#xD;
             rule out frozen shoulder&#xD;
&#xD;
          -  cooperative and able to communicate effectively&#xD;
&#xD;
          -  agree not to participate in any other studies during trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant pain from other joints requiring chronic analgesic therapy&#xD;
&#xD;
          -  presence of one or more conditions besides OA that could confound pain and functional&#xD;
             assessments&#xD;
&#xD;
          -  clinically apparent tense effusion, malalignment or instability in study shoulder&#xD;
&#xD;
          -  shoulder x-rays of acute fractures, sever loss of bone density, avascular necrosis or&#xD;
             severe deformity&#xD;
&#xD;
          -  inability to abstain from analgesic use other than rescue acetaminophen&#xD;
&#xD;
          -  IA injections of steroids to the study shoulder within 3 months or any other joint&#xD;
             within the prior month&#xD;
&#xD;
          -  IA injection of hyaluronic acid in the study shoulder within 9 months of baseline&#xD;
&#xD;
          -  allergic reaction to HA&#xD;
&#xD;
          -  any medical condition which in the opinion of the investigator makes the patient&#xD;
             unsuitable for inclusion or may compromise pain assessments of shoulder&#xD;
&#xD;
          -  uncontrolled hypothyroidism&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  planned surgical procedure&#xD;
&#xD;
          -  history or presence of septic arthritis of study joint or active skin disease or&#xD;
             infection in the area of the injection site&#xD;
&#xD;
          -  treatment with glucosamine/chondroitin initiated or unstable within 3 months of&#xD;
             baseline or change in physical therapy for the study shoulder within 1 month of&#xD;
             baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McKee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michaels Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michaels Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>degenerative arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02610504/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

